US Patent

US9061044 — Modulation of transthyretin expression

Composition of Matter · Assigned to Isis Pharmaceuticals Inc · Expires 2031-04-29 · 5y remaining

Vulnerability score 10/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects methods, compounds, and compositions that reduce expression of transthyretin mRNA and protein in an animal.

USPTO Abstract

Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.

Drugs covered by this patent

Patent Metadata

Patent number
US9061044
Jurisdiction
US
Classification
Composition of Matter
Expires
2031-04-29
Drug substance claim
Yes
Drug product claim
No
Assignee
Isis Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.